GeNeuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical tr…
Biotechnology
CH, Plan-les-Ouates [HQ]
Balance Sheet
11 Sheets · Starting from 2013In Million EUR. Margins, Growth Rates In %
| Metric | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | 4.00 | 9.00 | - - | - - | - - | - - | 9.00 | 10.00 | 12.00 | 11.00 | 6.00 | |
|
Current
|
3.00 | 8.00 | - - | - - | - - | - - | 7.00 | 7.00 | 9.00 | 9.00 | 2.00 | |
| Cash And Equivalents | 1.00 | 3.00 | - - | - - | - - | - - | 5.00 | 6.00 | 5.00 | 5.00 | 1.00 | |
| Assets | 4.00 | 9.00 | - - | - - | - - | - - | 9.00 | 10.00 | 12.00 | 11.00 | 6.00 | |
| Accounts Receivables (AR) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Inventory | - - | - - | - - | - - | -1.00 | -2.00 | - - | - - | - - | - - | - - | |
| Short Term Investments | 2.00 | 4.00 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Current Assets | - - | 1.00 | - - | - - | - - | - - | - - | - - | 3.00 | 2.00 | - - | |
|
Non Current
|
- - | - - | - - | - - | - - | - - | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | |
| Property, Plant, Equipment (Net) | - - | - - | - - | - - | - - | - - | - - | 1.00 | 1.00 | - - | - - | |
|
Intangible Assets
|
- - | - - | - - | - - | - - | - - | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Goodwill | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Long Term Investments | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | 1.00 | |
| Other Non Current Assets | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Liabilities | 1.00 | 2.00 | - - | - - | - - | - - | 14.00 | 4.00 | 7.00 | 10.00 | 20.00 | |
|
Current
|
1.00 | 2.00 | - - | - - | - - | - - | 10.00 | 2.00 | 3.00 | 3.00 | 6.00 | |
| Accounts Payable | - - | - - | - - | 1.00 | - - | 1.00 | -4.00 | - - | - - | - - | - - | |
| Short Term Debt | - - | - - | -6.00 | - - | -10.00 | - - | 7.00 | - - | - - | - - | - - | |
| Deferred Revenue | - - | - - | 6.00 | 8.00 | 10.00 | - - | - - | - - | - - | - - | -2.00 | |
| Tax Payable | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Current Liabilities | - - | 1.00 | -6.00 | -8.00 | -10.00 | - - | 1.00 | 2.00 | 2.00 | 2.00 | 5.00 | |
|
Non Current
|
- - | - - | - - | - - | - - | - - | 3.00 | 2.00 | 4.00 | 6.00 | 13.00 | |
| Long Term Debt | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | 6.00 | |
| Leasing Obligations | - - | - - | - - | - - | - - | - - | - - | 1.00 | - - | - - | - - | |
| Deferred Non Current Tax Liabilities | - - | - - | -9.00 | -5.00 | - - | - - | - - | - - | - - | - - | - - | |
| Other Non Current Liabilities | - - | - - | -9.00 | -5.00 | - - | - - | 3.00 | 2.00 | 4.00 | 6.00 | 7.00 | |
| Equity | 2.00 | 6.00 | - - | - - | - - | - - | -5.00 | 5.00 | 4.00 | 1.00 | -13.00 | |
| Stockholders' Equity | 2.00 | 6.00 | - - | - - | - - | - - | -5.00 | 5.00 | 4.00 | 1.00 | -13.00 | |
| Retained Earnings | -18.00 | -16.00 | - - | - - | - - | - - | -57.00 | -10.00 | -58.00 | -69.00 | -56.00 | |
| Common Stock | - - | - - | - - | - - | - - | - - | - - | - - | - - | 1.00 | 1.00 | |
| Preferred Stock | - - | - - | - - | - - | 1.00 | - - | - - | - - | - - | - - | - - | |
| Profit | -3.00 | 1.00 | - - | - - | - - | - - | -9.00 | -8.00 | -6.00 | -12.00 | -14.00 | |
| Dividends | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Minority Interest | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Stockholders' Equity | 21.00 | 23.00 | - - | - - | 1.00 | - - | 53.00 | 14.00 | 20.00 | 27.00 | - - | |
| Loss Other Compr. Income | - - | - - | - - | - - | -1.00 | - - | -2.00 | - - | 41.00 | 42.00 | 42.00 |